KMWM
WHWK

Keudell/Morrison Wealth Management’s Whitehawk Therapeutics WHWK Stock Holding History

Keudell/Morrison Wealth Management’s Portfolio WHWK Stock Details WHWK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,046
Closed -$40K – 178
2021
Q1 		$40K Buy
+2,046
New +$47.1K 0.02% 166

Other funds holding WHWK

AIM
Alerce Investment Management Chicago, Illinois $56.8M AUM 31.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
AICPI
ABG Innovation Capital Partners III Central, Hong Kong, Hong Kong $64.5K AUM 1.01% 1-Year Est. Return

Keudell/Morrison Wealth Management's WHWK Position: Q2 2021 in Review

Keudell/Morrison Wealth Management sold out of Whitehawk Therapeutics (WHWK) in Q2 2021, closing a stake of 2,046 shares — an estimated $40K sold.

Keudell/Morrison Wealth Management first reported a position in WHWK in Q1 2021 and held it in 1 quarter. The position peaked at $40K in Q1 2021. 42 funds tracked by Wall St. Rank hold WHWK as of Q2 2021.

  • Keudell/Morrison Wealth Management reported no remaining Whitehawk Therapeutics position as of Q2 2021 after selling out during the quarter.
  • Keudell/Morrison Wealth Management sold 2,046 Whitehawk Therapeutics shares in Q2 2021, an estimated $40K.
  • Keudell/Morrison Wealth Management first reported a position in Whitehawk Therapeutics in Q1 2021 and held it in 1 quarter.
  • Keudell/Morrison Wealth Management's Whitehawk Therapeutics position peaked at $40K in Q1 2021.
  • 42 funds tracked by Wall St. Rank held Whitehawk Therapeutics as of Q2 2021.

Based on Keudell/Morrison Wealth Management's 13F filing for Q2 2021, filed 13 Jul 2021.